RxDoctor Payments Data

Schyler Brown, NP

Family · Jackson, MSNPI 1568855179

Payments from drug & device makers

$882in general payments, 2019–2025

Across 29 payments — averaging $30.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$386
  • Abbott$190
  • AstraZeneca$146
  • Boehringer Ingelheim$68
  • Sanofi-aventis U.S. LLC$31
  • Johnson & Johnson$28
  • plus $34 from 2 others

What the payments were for

  • Food & beverage$882100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$882 in reported general payments places this provider in the 65th percentile of 3,007 family providers in Mississippi.

See all family providers in Mississippi

Medicare billing

Part B allowed, 2024
$3,998
Medicare patients
41
Services billed
71

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin128$195,143
EliquisApixaban52$46,119
OzempicSemaglutide36$46,019
MounjaroTirzepatide26$43,689
Trelegy ElliptaFluticasone/Umeclidin/Vilanter45$41,813
Trijardy XrEmpaglifloz/Linaglip/Metformin38$35,187
LinzessLinaclotide24$34,300
FarxigaDapagliflozin Propanediol30$33,456
RybelsusSemaglutide24$31,816
Tresiba Flextouch U-100Insulin Degludec21$13,651
SymbicortBudesonide/Formoterol Fumarate24$11,408
Breo ElliptaFluticasone/Vilanterol13$8,441
Atrovent HfaIpratropium Bromide11$5,386
Albuterol Sulfate HfaAlbuterol Sulfate119$5,000
Novolog FlexpenInsulin Aspart19$4,480

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Trijardy Xr$68$230,329166 claims
Novo NordiskOzempic, Rybelsus$386$77,83560 claims
AstraZenecaFarxiga, Symbicort$146$44,86354 claims
Lilly USA, LLCMounjaro$16$43,68926 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,007 family providers in Mississippi.

Other family in Jackson

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →